CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $22.20.

Several research analysts have commented on the company. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Canaccord Genuity Group decreased their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th.

CeriBell Price Performance

Shares of CBLL remained flat at $19.55 during trading hours on Friday. The company had a trading volume of 721,324 shares, compared to its average volume of 373,296. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. CeriBell has a one year low of $10.85 and a one year high of $24.33. The company has a market cap of $741.79 million, a price-to-earnings ratio of -11.99 and a beta of 0.77. The firm has a 50 day moving average price of $18.78 and a two-hundred day moving average price of $19.72.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, analysts anticipate that CeriBell will post -1.69 EPS for the current fiscal year.

Insider Activity at CeriBell

In other news, CTO Raymond Woo sold 11,104 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $20.44, for a total transaction of $226,965.76. Following the completion of the sale, the chief technology officer owned 197,648 shares in the company, valued at $4,039,925.12. This trade represents a 5.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Joseph Michael Taylor sold 5,500 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $18.41, for a total value of $101,255.00. Following the completion of the transaction, the director owned 61,573 shares in the company, valued at $1,133,558.93. This represents a 8.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 350,789 shares of company stock valued at $6,887,691 in the last three months. Company insiders own 20.10% of the company’s stock.

Hedge Funds Weigh In On CeriBell

Large investors have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of CeriBell during the 1st quarter worth $27,000. Caitong International Asset Management Co. Ltd lifted its position in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the third quarter worth about $33,000. CWM LLC increased its position in shares of CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.